Tomaralimab

• Description:

  Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury[1][2][3][4][5].

• Product Name Alternative:

  OPN-305

• UNSPSC:

  12352203

• Target:

  Interleukin Related; MyD88; NOD-like Receptor (NLR) ; Tau Protein; Toll-like Receptor (TLR)

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Immunology/Inflammation; Neuronal Signaling

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/tomaralimab.html

• Purity:

  99.42

• Solubility:

  10 mM in DMSO

• Smiles:

  [Tomaralimab]

• Molecular Weight:

  (145.32 kDa)

• References & Citations:

  [1]GuillermoGarcia-ManeroMD, et al. A Clinical Study of Tomaralimab (OPN-305), a Toll-like Receptor 2 (TLR-2) Antibody, in Heavily Pre-Treated Transfusion Dependent Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received and Failed on Prior Hypomethylating Agent (HMA) Therapy. Blood, 2018, 798.|[2]Kim Y, et al. TLR2 immunotherapy suppresses neuroinflammation, tau spread, and memory loss in rTg4510 mice. Brain Behav Immun. 2024 Oct;121:291-302. |[3]Yeo H, et al. Therapeutic potential of a systemically applied humanized monoclonal antibody targeting Toll‑like receptor 2 in atopic‑dermatitis‑like skin lesions in a mouse model. Biomed Rep. 2024 Dec 30;22 (3) :41.|[4]Lundy J, et al. TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma. Oncogene. 2021 Oct;40 (41) :6007-6022.|[5]Arslan F, et al. Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv. 2012 Apr;5 (2) :279-87.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  Phase 2

• Isoform:

  IL-1; IL-6; IL-8; NLRP3

• CAS Number:

  1449294-76-1